Skip to content

Lung Cancer Health Center

Font Size

Stages IA and IB NSCLC Treatment

    Standard Treatment Options for Stages IA and IB NSCLC

    Standard treatment options for stage IA NSCLC and IB NSCLC include the following:

    Recommended Related to Lung Cancer

    Treatment Option Overview for NSCLC

    In NSCLC, results of standard treatment are poor except for the most localized cancers. All newly diagnosed patients with NSCLC are potential candidates for studies evaluating new forms of treatment. Surgery is the most potentially curative therapeutic option for this disease. Postoperative chemotherapy may provide an additional benefit to patients with resected NSCLC. Radiation therapy combined with chemotherapy can produce a cure in a small number of patients and can provide palliation in most...

    Read the Treatment Option Overview for NSCLC article > >

    1. Surgery.
    2. Radiation therapy.

    Chemotherapy and radiation therapy have not been shown to improve outcomes in stage I NSCLC that has been completely resected.

    Surgery

    Surgery is the treatment of choice for patients with stage I NSCLC. A lobectomy or segmental, wedge, or sleeve resection may be performed as appropriate. Patients with impaired pulmonary function are candidates for segmental or wedge resection of the primary tumor. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery. The immediate postoperative mortality rate is age related, but a 3% to 5% mortality rate with lobectomy can be expected.[1]

    Evidence (surgery):

    1. The Lung Cancer Study Group conducted a randomized study (LCSG-821) that compared lobectomy with limited resection for patients with stage I lung cancer. Results of the study showed the following:[2]
      • A reduction in local recurrence for patients treated with lobectomy compared with those treated with limited excision.
      • No significant difference in overall survival (OS).
    2. Similar results have been reported from a nonrandomized comparison of anatomic segmentectomy and lobectomy.[3]
      • A survival advantage was noted with lobectomy for patients with tumors larger than 3 cm but not for those with tumors smaller than 3 cm.
      • The rate of locoregional recurrence was significantly less after lobectomy, regardless of primary tumor size.
    3. A study of stage I patients showed the following:[4]
      • Those treated with wedge or segmental resections had a local recurrence rate of 50% (i.e., 31 recurrences out of 62 patients) despite having undergone complete resections.[4]
    4. The Cochrane Collaboration group reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[5] A pooled analysis of three trials reported the following:
      • Four-year survival was superior in patients with resectable stage I, II, or IIIA NSCLC who underwent resection and complete ipsilateral mediastinal lymph node dissection (CMLND), compared with those who underwent resection and lymph node sampling; the hazard ratio (HR) was estimated to be 0.78 (95% confidence interval [CI], 0.65–0.93, P = .005).[5][Level of evidence: 1iiA]
      • There was a significant reduction in any cancer recurrence (local or distant) in the CMLND group (relative risk [RR], 0.79; 95% CI, 0.66–0.95; P = .01) that appeared mainly because of a reduction in the number of distant recurrences (RR, 0.78; 95% CI, 0.61–1.00; P = .05).
      • There was no difference in operative mortality.
      • Air leak lasting more than 5 days was significantly more common in patients assigned to CMLND (RR, 2.94; 95% CI, 1.01–8.54; P = .05).
    5. Current evidence suggests that lung cancer resection combined with CMLND is associated with a small-to-modest improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal nodes in patients with stage I, II, or IIIA NSCLC.[5][Level of evidence: 1iiA]
    6. CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030).[6]
      • Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[6]
      1|2|3|4

      Today on WebMD

      Broken cigarette
      Do you know the myths from the facts?
      man with a doctor
      Our health check will steer you in the right direction.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      15 Cancer Symptoms Men Ignore
      FEATURE
      Lung Cancer Risks Myths and Facts
      SLIDESHOW
       
      cancer fighting foods
      SLIDESHOW
      Improving Lung Cancer Survival Targeted Therapy
      VIDEO
       
      Lung Cancer Surprising Differences Between Sexes
      VIDEO
      Pets Improve Your Health
      SLIDESHOW
       
      Vitamin D
      SLIDESHOW
      Lung Cancer Surgery Options
      VIDEO
       

      WebMD Special Sections